Antibody Drug Conjugates:
Targeted Cancer Therapies at the Intersection of Chemistry, Biology, and Engineering
Friday, June 27, 2025
The 23rd Annual Koch Institute Symposium on Antibody Drug Conjugates: Targeted Cancer Therapies at the Intersection of Chemistry, Biology, and Engineering will take place on Friday, June 27, 2025. Kicking off with 2022 Nobel Prize winner Carolyn Bertozzi, our speaker lineup features an array of industry and academic leaders who will discuss current advancements and challenges in deploying antibody drug conjugates (ADCs) as anti-cancer agents. We cordially invite scientists, oncologists, and any other member of the biomedical community to join us in a day of engaging talks, stimulating conversations with colleagues, and of course camaraderie in our collective fight against cancer.
Agenda
9:00 a.m. - 9:10 a.m. Opening remarks
Matthew Vander Heiden
Director, MIT Koch Institute
9:10 a.m. – 10:00 a.m. Keynote
Introduction: Jessica Stark, MIT Koch Institute
Carolyn Bertozzi
Stanford University
Topic: Antibody drug conjugate biological chemistry
10:00 a.m. – 12:00 pmSession One
Peter Senter
Fred Hutchinson Cancer Center
Antibody Drug Conjugates for Cancer Therapy: From Early Stage Research to Clinically Approved Drugs
Gerold Meinhardt
Daiichi Sankyo
Trastuzumab Deruxtecan: The Redefinition of HER2-targeted Therapy
Alison Betts
Takeda Pharmaceuticals
More than the sum of their parts: Integrating data and knowledge of ADCs in a Quantitative Systems Pharmacology platform model to predict efficacy and toxicity
Timothy Lowinger
Mersana Therapeutics
Development of a STING-agonist ADC Platform: A Targeted Approach to Immunostimulation
12:00 p.m. – 1:30 p.m.Lunch Break
1:30 p.m. – 2:30 p.m.Session Two: Short Presentations
Laurie Boyer
MIT Koch Institute
Traffic control: High resolution mapping of ADCs within the lysosomal compartment
Dane Wittrup
MIT Koch Institute
Topic: Noncovalent capture antibody drug conjugates
Jeremiah Johnson
MIT Koch Institute
The ABCs of Antibody-Bottlebrush Conjugates
Daša Lipovšek
Aktis Oncology
Miniproteins for targeted radiotherapy
2:30 p.m. – 4:30 p.m.Session Three
Greg Thurber
University of Michigan
Designing ADCs for Efficient Tumor Tissue Penetration and Clinical Efficacy
Puja Sapra
AstraZeneca
Topic: Antibody drug conjugate payloads and linker chemistry
Michael Seganish
Merck
Navigating Undesired Payload Release
Thank you to our sponsors!
Platinum
Silver
Bronze
